Mangoceuticals (MGRX) vs Progyny (PGNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Progyny is the larger company by market cap ($2.14 billion vs $9.3 million), about 229.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | MGRX | PGNY |
|---|---|---|
| Share price | $0.4324 | $27.83 |
| Market cap | $9.33M | $2.14B |
| 1-day change | -2.55% | +1.02% |
| YTD return | — | +7.28% |
| 1-year return | — | +37.75% |
| 5-year return | — | -50.79% |
| P/E ratio (TTM) | — | 30.25 |
| Forward P/E | — | 12.00 |
| EPS (TTM) | $-1.02 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.75 | $33.07 |
| 52-week low | $0.162 | $16.10 |
| Distance from 52-week high | -84.28% | -15.83% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +23.68% |
| Average volume | 12.83M | 1.14M |
| Shares outstanding | 21.57M | 76.73M |
| Employees | — | 835 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Progyny is about 229.0 times larger than Mangoceuticals by market value ($2.14B vs $9.33M).
About Progyny
PGNY stock →Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.
Health Care · Misc Health and Biotechnology Services · 835 employees
MGRX vs PGNY FAQ
Which is bigger, Mangoceuticals or Progyny?
Progyny (PGNY) is larger, with a market capitalization of $2.14B compared with $9.33M for Mangoceuticals (MGRX).
Are Mangoceuticals and Progyny in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.